Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Retatrutide vs semaglutide: the trial

Lilly's reported TRANSCEND-T2D-2 results put retatrutide ahead of semaglutide on average HbA1c and weight change, with important limits.

Why we wrote this. The head-to-head result needs a careful distinction between sponsor-reported topline numbers and a complete public trial record.

In this article (5 sections)
  1. What TRANSCEND-T2D-2 is testing
  2. What Lilly reported at 80 weeks
  3. The trade-off in the reported data
  4. What we do not yet know
  5. Bottom line

Lilly has reported that retatrutide produced larger average reductions in HbA1c and body weight than semaglutide in TRANSCEND-T2D-2, a Phase 3 head-to-head study in adults with type 2 diabetes. The result is notable, but it is not yet a peer-reviewed publication or a posted ClinicalTrials.gov results record. For now, the numbers should be read as sponsor-reported topline findings, with the trial design and status available in the registry[1][2].

The comparison is between two investigational or prescription-drug treatment pathways, not a reason to self-select a medicine. Retatrutide remains an investigational drug. Semaglutide is covered separately in our semaglutide evidence guide, while our retatrutide guide explains why trial evidence and product availability are not the same thing.

What TRANSCEND-T2D-2 is testing

TRANSCEND-T2D-2 is a Phase 3, randomized, multicentre, open-label study sponsored by Eli Lilly. It compares once-weekly retatrutide with once-weekly semaglutide in adults with type 2 diabetes whose glucose control was inadequate on metformin, with or without an SGLT2 inhibitor. The registry lists an estimated enrolment of 1,250 people and an 80-week primary endpoint for change in HbA1c, a blood test that reflects average glucose exposure over roughly the preceding two to three months[1].

The study record gives useful context that a headline cannot. It uses an active comparator rather than placebo and is open-label, meaning participants and investigators know the assigned treatment. It also measures body-weight change, HbA1c thresholds, lipids and blood pressure as secondary outcomes. The primary-completion date is recorded as 27 August 2026; the registry was still marked active, not recruiting, with final completion estimated for February 2027 when last updated in September[1].

What Lilly reported at 80 weeks

According to Lilly's reported topline results, relayed by BioPharma Dive, the 12 mg retatrutide group had a mean HbA1c reduction of 2.2 percentage points at week 80, compared with 1.8 percentage points for semaglutide. The 9 mg retatrutide group also reduced HbA1c by 2.2 percentage points, although the report says its comparison with semaglutide was statistically nominal. That qualifier matters: it means the result should not be treated as the same level of confirmatory comparison described for the higher dose[2].

The reported average body-weight changes were 21% with 12 mg retatrutide, 20% with 9 mg retatrutide, and 9% with semaglutide. Retatrutide activates GLP-1, GIP and glucagon receptors, whereas semaglutide acts on the GLP-1 receptor. That pharmacology is a plausible reason researchers are interested in the comparison, but it does not by itself establish which treatment is appropriate for an individual person[2].

The trade-off in the reported data

The same report describes more discontinuations attributed to side effects in the retatrutide groups: 8% at 12 mg and 5% at 9 mg, versus 3% with semaglutide. This is not a small detail to place beneath the efficacy figures. A greater average change in a trial does not cancel a higher treatment-discontinuation rate, and topline reporting alone does not show the full pattern of adverse events, their severity, or how they were managed[2].

The registry's eligibility criteria also limit who the findings can describe. Participants had type 2 diabetes, HbA1c from 7.0% to 10.5%, a BMI of at least 25, and stable metformin treatment with or without an SGLT2 inhibitor before screening. The study excluded, among other groups, people with recent severe hypoglycaemia, pancreatitis, some serious cardiovascular events, or a personal or family history of medullary thyroid carcinoma or MEN2[1]. Those details make it inappropriate to generalise the results to everyone seeking weight loss or diabetes treatment.

What we do not yet know

ClinicalTrials.gov currently shows no posted results for this study, and no peer-reviewed paper reporting TRANSCEND-T2D-2 was identified for this article. That leaves important questions unresolved: the complete adverse-event tables, analysis population, subgroup findings, protocol handling of missing data, and the final statistical report. The registry also lists final study completion after the reported 80-week primary endpoint, so the public record may still change[1].

Readers should also avoid treating the dose arms reported here as instructions. They are study interventions under a specific protocol, not a dosing plan. Decisions about diabetes medicines involve diagnosis, current treatment, contraindications, adverse-effect history, access and monitoring, and belong with a qualified healthcare professional.

Bottom line

The available sponsor-reported readout supports a narrow conclusion: in this specific 80-week Phase 3 comparison, the 12 mg retatrutide arm had larger reported average reductions in HbA1c and weight than semaglutide, alongside more discontinuations for side effects. It does not establish long-term safety, regulatory approval, or a universal treatment ranking. Watch the retatrutide clinical-trial evidence as fuller results become publicly available.[1][2]

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

What did TRANSCEND-T2D-2 compare?

TRANSCEND-T2D-2 is a Phase 3 study comparing once-weekly retatrutide with once-weekly semaglutide in adults with type 2 diabetes whose glucose control was inadequate on metformin, with or without an SGLT2 inhibitor. It is an active-comparator, open-label study.

Did retatrutide beat semaglutide for HbA1c?

Lilly reported that the 12 mg retatrutide arm reduced HbA1c by an average 2.2 percentage points at week 80 versus 1.8 percentage points with semaglutide. These are sponsor-reported topline findings, not yet a peer-reviewed publication or posted registry result.

Were side effects different between the groups?

BioPharma Dive's report of Lilly's topline data says 8% of people in the 12 mg retatrutide group and 5% in the 9 mg group discontinued because of side effects, compared with 3% in the semaglutide group. Full adverse-event data have not yet been posted in the trial registry.

Is retatrutide approved for type 2 diabetes?

This trial result does not itself confer approval. The registry describes retatrutide as the experimental intervention in an active, not recruiting Phase 3 study. Regulatory status depends on decisions by medicines regulators, not on a single topline announcement.

Sources

  1. [1]ClinicalTrials.gov: NCT06260722, TRANSCEND-T2D-2, Effect of Retatrutide Compared With Semaglutide in Adults With Type 2 DiabetesTier 1 · primary↩
  2. [2]BioPharma Dive: Lilly's triple-G drug tops Novo's Ozempic in diabetes trial (reporting Lilly's 28 October 2026 topline announcement)Tier 2 · expert↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars